News

Early-onset Alzheimer's, affecting individuals under 65, presents unique challenges with memory, thinking, and daily ...
IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer's disease and ...
Lantheus remains strong with PYLARIFY growth, Alzheimer’s potential, and solid financials despite stock volatility and risks.
Unlike expensive positron emission tomography (PET) scans or invasive lumbar punctures, the new blood test measures the ratio ...
Nonmodifiable risk factors for DLB include age and family history. Risk increases substantially in individuals with a ...
Radiopharmaceuticals have become indispensable tools in precision medicine, revolutionizing diagnostic imaging and targeted ...
President Trump has issued two executive orders addressing what he calls "gender ideology," one of which declares the federal government's policy to recognize "two sexes, male and the female," and a ...
The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.
The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is ...
Using brain gene expression maps from the Allen Human Brain Atlas, the researchers tested the degree to which Alzheimer’s risk genes explain the patterns of both actual and residual tau. This allowed ...
It's been recognized for some time that Alzheimer's disease affects brain regions differently and that tau—a protein known to ...
After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and new therapeutic targets fueling cautious hope.